Advances in insulin therapy from discovery to β‐cell replacement

Insulin therapy using insulin purified from porcine or bovine pancreas revolutionized diabetes therapy in the 1920s. A series of advances including cloning human insulin cDNA enabled the development of recombinant human insulin with improved features. Insulin treatment for diabetes may well be upend...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakurai, Teruaki, Kubota, Sodai, Kato, Takehiro, Yabe, Daisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Update
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807147/
https://www.ncbi.nlm.nih.gov/pubmed/36074333
http://dx.doi.org/10.1111/jdi.13902
_version_ 1784862656998408192
author Sakurai, Teruaki
Kubota, Sodai
Kato, Takehiro
Yabe, Daisuke
author_facet Sakurai, Teruaki
Kubota, Sodai
Kato, Takehiro
Yabe, Daisuke
author_sort Sakurai, Teruaki
collection PubMed
description Insulin therapy using insulin purified from porcine or bovine pancreas revolutionized diabetes therapy in the 1920s. A series of advances including cloning human insulin cDNA enabled the development of recombinant human insulin with improved features. Insulin treatment for diabetes may well be upended by β‐cell replacement therapy in the coming decades.[Image: see text]
format Online
Article
Text
id pubmed-9807147
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98071472023-01-04 Advances in insulin therapy from discovery to β‐cell replacement Sakurai, Teruaki Kubota, Sodai Kato, Takehiro Yabe, Daisuke J Diabetes Investig Update Insulin therapy using insulin purified from porcine or bovine pancreas revolutionized diabetes therapy in the 1920s. A series of advances including cloning human insulin cDNA enabled the development of recombinant human insulin with improved features. Insulin treatment for diabetes may well be upended by β‐cell replacement therapy in the coming decades.[Image: see text] John Wiley and Sons Inc. 2022-09-08 /pmc/articles/PMC9807147/ /pubmed/36074333 http://dx.doi.org/10.1111/jdi.13902 Text en © 2022 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Update
Sakurai, Teruaki
Kubota, Sodai
Kato, Takehiro
Yabe, Daisuke
Advances in insulin therapy from discovery to β‐cell replacement
title Advances in insulin therapy from discovery to β‐cell replacement
title_full Advances in insulin therapy from discovery to β‐cell replacement
title_fullStr Advances in insulin therapy from discovery to β‐cell replacement
title_full_unstemmed Advances in insulin therapy from discovery to β‐cell replacement
title_short Advances in insulin therapy from discovery to β‐cell replacement
title_sort advances in insulin therapy from discovery to β‐cell replacement
topic Update
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807147/
https://www.ncbi.nlm.nih.gov/pubmed/36074333
http://dx.doi.org/10.1111/jdi.13902
work_keys_str_mv AT sakuraiteruaki advancesininsulintherapyfromdiscoverytobcellreplacement
AT kubotasodai advancesininsulintherapyfromdiscoverytobcellreplacement
AT katotakehiro advancesininsulintherapyfromdiscoverytobcellreplacement
AT yabedaisuke advancesininsulintherapyfromdiscoverytobcellreplacement

Ejemplares similares